During the past decade, Chest Medicine Associates conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 5 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 5 clinical trials were completed. i.e. 500% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Chest Medicine Associates" are "Pulmonary Arterial Hypertension" (6 trials), "Pulmonary Hypertension" (4 trials), "Cardiovascular Diseases" (2 trials), "Connective Tissue Diseases" (2 trials) and "Familial Primary Pulmonary Hypertension" (2 trials). Many other conditions were trialed in "Chest Medicine Associates" in a lesser frequency.

Most popular intervention types in "Chest Medicine Associates" are "Drug" (8 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Oral treprostinil" (3 trials), "Placebo" (3 trials), "Ralinepag" (2 trials), "ubenimex" (2 trials) and "Inhaled Treprostinil" (1 trials). Other intervention names were less common.

The vast majority of trials in "Chest Medicine Associates" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Chest Medicine Associates". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 3 completed trials in Chest Medicine Associates, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Chest Medicine Associates, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".